Unicycive Therapeutics (Unicycive Therapeutics) Total Payout Ratio : 0.00 (As of Jun. 23, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Unicycive Therapeutics Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Unicycive Therapeutics's current Total Payout Ratio is 0.00.

Unicycive Therapeutics Total Payout Ratio Historical Data

The historical data trend for Unicycive Therapeutics's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Unicycive Therapeutics Total Payout Ratio Chart

Unicycive Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Payout Ratio

0.54

0.06

2.22

Unicycive Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Payout Ratio	Get a 7-Day Free Trial													-	-	-	-	-

Competitive Comparison of Unicycive Therapeutics's Total Payout Ratio

For the Biotechnology subindustry, Unicycive Therapeutics's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Unicycive Therapeutics's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Unicycive Therapeutics's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Unicycive Therapeutics's Total Payout Ratio falls into.

Unicycive Therapeutics Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Unicycive Therapeutics's Total Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	0	+	0)	/	-30.544
	=	0.00

Unicycive Therapeutics's Total Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	0	+	0)	/	-20.963
	=	0.00

Unicycive Therapeutics Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Unicycive Therapeutics's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Unicycive Therapeutics (Unicycive Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Unicycive Therapeutics Inc (NAS:UNCY) » Definitions » Total Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

4300 El Camino Real, Suite 210, Los Altos, CA, USA, 94022

Website

https://www.unicycive.com

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.

Executives

Sandeep Laumas	director	8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
John L Ryan	director	C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Sara Kenkare-mitra	director	C/O ALECTOR, INC, 131 OYSTER POINT BLVD, SUITE 600, SOUTH SAN FRANCISCO CA 94080
Gaurav Aggarwal	director	C/O PANORAMA CAPITAL, 2440 SAND HILL ROAD, SUITE 302, MENLO PARK CA 94025
Douglas Jermasek	other: EVP of Corporate Strategy	4300 EL CAMINO REAL, SUITE 210, LOS ALTOS CA 94022
Brigitte Schiller	director	UNICYCIVE THERAPEUTICS, INC., 5150 EL CAMINO REAL, SUITE A-32, LOS ALTOS CA 94022
John Townsend	officer: Chief Financial Officer	15150 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Pramod Gupta	officer: EVP, Pharmaceuticals and BD	UNICYCIVE THERAPEUTICS, INC., 5150 EL CAMINO REAL, SUITE A-32, LOS ALTOS CA 94022
Shalabh K. Gupta	director, officer: CEO	UNICYCIVE THERAPEUTICS, INC., 5150 EL CAMINO REAL, SUITE A-32, LOS ALTOS CA 94022